Zuranolone

Oral 14-day allopregnanolone-analog GABA-A positive allosteric modulator; the first FDA-approved pill for postpartum depression.

Zuranolone carries a boxed warning that it can impair the ability to drive and to perform other potentially hazardous activities; because of its sedative effects, patients are advised not to drive or operate heavy machinery for at least 12 hours after each dose. The most common adverse effects are dose-related central nervous system depression, including somnolence, dizziness, sedation, and fatigue; these effects are additive with alcohol, benzodiazepines, opioids, and other central nervous system depressants.

Like other antidepressants it carries class warnings regarding possible emergence or worsening of suicidal thoughts and behaviors, particularly in younger adults, and mandates monitoring. Because it can cause fetal harm in animal studies, effective contraception is advised during and for one week after treatment, and its transfer into breast milk means nursing decisions require clinical judgment. It is a substrate of the liver enzyme CYP3A4, so strong inducers or inhibitors of that pathway can alter its exposure and require dose adjustment. Zuranolone is a Schedule IV controlled substance, reflecting a recognized but comparatively low potential for misuse relative to older sedative-hypnotics.

Zuranolone acts synergistically with benzodiazepines like diazepam through a pharmacodynamic mechanism at GABA-A receptors ^[7]. Although both are positive allosteric modulators of GABA-A, zuranolone and benzodiazepines bind to distinct, non-overlapping sites on the receptor; when combined, they produce additive GABA enhancement and increased central nervous system depression. This synergy has been confirmed in models where zuranolone and diazepam together produce greater current amplification than either agent alone ^[27]. Clinical co-use requires dose adjustment and careful monitoring for oversedation.

Zuranolone also shows synergistic effects with other GABA-A modulators such as muscimol, another positive allosteric modulator operating through a distinct mechanism ^[27]. The interaction is pharmacodynamic; neither drug changes the other's blood levels. No major pharmacokinetic interactions with hepatic enzyme inhibitors or inducers have been documented in published literature, and interactions with most other drug classes remain understudied.

Checking a whole stack? Run it through interactions + stacks.

Zuranolone emerged from Sage Therapeutics' neuroactive steroid program, which set out to translate the antidepressant and anticonvulsant properties of the endogenous neurosteroid allopregnanolone into practical medicines. The program first yielded brexanolone, an intravenous allopregnanolone formulation approved in 2019 for postpartum depression, but its 60-hour infusion and inpatient monitoring limited access.

Chemists therefore designed an orally bioavailable analog, SAGE-217, replacing part of the steroid framework with a metabolically stable pyrazole group to survive first-pass metabolism and support daily tablets. A 2019 phase 2 trial published in the New England Journal of Medicine by Gunduz-Bruce and colleagues reported robust and rapid reductions in depressive symptoms in major depressive disorder, generating substantial interest in a fast-acting, short-course oral antidepressant.

Sage partnered with Biogen (which assigned the code BIIB125) to advance a broad program spanning major depressive disorder and postpartum depression, with trials named for landscape features. The major depressive disorder results proved inconsistent, as the MOUNTAIN study missed its primary endpoint while the WATERFALL study succeeded, whereas the postpartum program, including the ROBIN and SKYLARK trials, was more uniformly positive.

In August 2023 the Food and Drug Administration approved zuranolone under the brand name Zurzuvae for postpartum depression but issued a complete response letter declining approval for major depressive disorder, concluding the evidence there was insufficient. The approval was nonetheless historic as the first oral drug indicated specifically for postpartum depression.

Within psychiatry zuranolone is regarded as a landmark for two reasons: it validated the neurosteroid hypothesis of postpartum depression in an orally practical form, and it demonstrated that a rapid-acting antidepressant effect could be achieved with a short, defined course rather than open-ended daily dosing. Clinicians and patient advocates welcomed an at-home oral option that removes the inpatient infusion burden of brexanolone.

At the same time its reputation is tempered by the failure to gain approval for major depressive disorder, by questions about the durability of benefit after the 14-day course ends, and by the sedation and driving-impairment warnings that constrain everyday use. Commentators have also debated its cost and its place relative to established antidepressants. In the nootropics and neuroscience community it is discussed less as a cognitive enhancer and more as a proof of concept that extrasynaptic delta-subunit GABA-A receptors are a druggable target for mood disorders, alongside related tool compounds and the broader neurosteroid field.